On Tuesday, Stifel analysts adjusted their outlook on Zoetis Inc . (NYSE: NYSE:), a leader in animal health, by reducing the price target to $180 from the prior target of $210. Despite this change, the firm maintained its Buy rating on the company’s shares. According to InvestingPro data, Zoetis currently trades at a P/E ratio of 30.7x, with analysts setting price targets ranging from $178 to $248.
The adjustment follows a challenging year within the medical technology sector, particularly for consumer-focused subsectors. Stifel’s analysis highlighted that nearly all stocks within their coverage, spanning Dental, Animal Health, and Aesthetics verticals, underperformed year-over-year.
Specifically, the Animal Health segment saw significant declines, with IDEXX Laboratories, Elanco, and Zoetis stocks dropping by 26%, 19%, and 17% respectively.
This performance starkly contrasted with the broader S&P 500’s 23% gain and the iShares U.S. Medical (TASE:) Devices ETF (IHI) 8% increase. Trupanion (NASDAQ:) was noted as an outlier, rising by 58% after rebounding from its previous year’s losses, leaving its two-year performance relatively flat.
Looking forward to 2025, Stifel’s analysts provided insights on Zoetis. They cited several positive factors, including the resilience of key franchises, projected revenue growth reaching near all-time highs, and anticipated acceleration of innovation in late 2025 and 2026.
However, there are concerns that may impact the company’s performance. Stifel’s due diligence raised safety issues regarding Zoetis’s pain management drug for dogs, Librela, leading to lowered estimates for the product.
Additionally, the analysts expect increased competition in the Animal Dermatology (AD) and Parasiticide markets in 2025. The company’s revenue growth of 9.3% in the last twelve months and projected 8% growth for 2024, as reported by InvestingPro, suggest continued momentum despite these challenges.
Zoetis, known for its products and services that improve animal health, has faced a variety of market pressures. Yet, the company’s innovation track record and market presence continue to be recognized by Stifel as reasons to maintain a positive long-term outlook. Despite the lowered price target, the Buy rating suggests that Stifel sees potential value in Zoetis shares at the adjusted price level.
The company has maintained dividend payments for 13 consecutive years and demonstrates strong cash flows that sufficiently cover interest payments, according to InvestingPro, which offers 11 additional valuable insights about Zoetis’s financial health and market position.
In other recent news, Zoetis Inc., a global leader in animal health, has announced significant leadership changes and strong financial performance.
Jamie Brannan has been appointed as Chief Commercial Officer in a strategic move to enhance the company’s commercial strategy and expand its global market presence. Additionally, there are upcoming changes with Wafaa Mamilli leaving in early 2025, to be replaced by Keith Sarbaugh as Executive Vice President and Chief Digital & Technology Officer, and Jared Shriver stepping into the role of President of U.S. Operations.
These recent developments coincide with a robust Q3 growth reported by Zoetis. The company saw a 14% operational revenue increase to $2.4 billion and a 15% surge in adjusted net income to $716 million, largely attributed to demand for its osteoarthritis pain treatments, Librela and Solensia, and the continued success of the Simparica franchise and dermatology portfolio. Consequently, Zoetis has revised its revenue guidance for 2024, now projecting between $9.2 billion and $9.3 billion, with adjusted net income estimated to fall between $2.67 billion and $2.695 billion.
Despite expecting some deceleration in Q4 growth due to recent divestitures, Zoetis anticipates maintaining strong performance into 2025. The company’s confidence in its key franchises and aims for Librela to become a $1 billion franchise, along with strategic partnerships and a focus on high-growth areas, are expected to fuel this future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
